ImmunityBio
IBRX
141 hedge funds and large institutions have $209M invested in ImmunityBio in 2021 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 47 increasing their positions, 35 reducing their positions, and 19 closing their positions.
79% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 19
34% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 35
12% more funds holding
Funds holding: 126 → 141 (+15)
0.51% more ownership
Funds ownership: 8.16% → 8.67% (+0.51%)
33% less capital invested
Capital invested by funds: $311M → $209M (-$102M)
60% less call options, than puts
Call options by funds: $2.96M | Put options by funds: $7.39M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$6.74M |
| 2 |
Rafferty Asset Management
New York
|
+$2.81M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.83M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$1.81M |
| 5 |
Millennium Management
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$4.31M |
| 2 |
BlackRock
New York
|
-$1.58M |
| 3 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$1.26M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.01M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$974K |
IBRX Hedge Fund Activity: Q4 2021 in Review
141 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2021, worth a combined $209M — down 33% from $311M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IBRX positions and 19 closed out — a net gain of 15 holders — while 47 added to existing stakes and 35 trimmed.
The largest buyer was State Street, adding an estimated $6.74M. The largest seller was Northern Trust, cutting an estimated $4.31M.
- 141 institutional investors held ImmunityBio (IBRX) as of Q4 2021, up from 126 in Q3 2021.
- Funds reported $209M of ImmunityBio stock for Q4 2021, down 33% quarter-over-quarter.
- 34 funds opened new ImmunityBio positions in Q4 2021 and 19 closed out, a net change of +15 holders.
- The largest ImmunityBio buyer in Q4 2021 was State Street, an estimated $6.74M added.
- The largest ImmunityBio seller in Q4 2021 was Northern Trust, an estimated $4.31M sold.
Based on aggregated 13F filings for Q4 2021.